

18. Babjuk M, Košťířová M, Mudra K, et al. Místo neinvazivních testů (BTA STAT, BTA TRAK, UBC RAPID, UBC IRMA) a cytologie při sledování pacientů s povrchovými nádory močového měchýře. *Ces Urol*. 2001; 5(3): 9–13.
19. Szakácsová M, Soukup V, Babjuk M, et al. Expres genů BCL-2 a BAX-1 ve tkáni Ta, T1 uroteliálních karcinomů močového měchýře a jejich prognostický význam. *Ces Urol* 2013; 17(3): 204–209.
20. Peší M, Soukup V, Babjuk M, et al. Význam stanovení močové hladiny TATI (tumour associated trypsin inhibitor) pro diagnostiku a prognózu tumorů močového měchýře. *Ces Urol*. 2015; 19(1): 44–50.
21. Lotan Y, Roehrborn CG. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. *Urology* 2003; 61(1): 109–18; discussion 18.
22. Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. *Clin Cancer Res*. 1998; 4(10): 2511–2520.
23. Soloway MS, Briggman V, Carpinito GA, et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment. *J Urol*. 1996; 156(2 Pt 1): 363–367.
24. Cappellen D, De Oliveira C, Ricol D, et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. *Nat Genet*. 1999; 23(1): 18–20.
25. Allory Y, Beukers W, Sagrera A, et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. *Eur Urol*. 2014; 65(2): 360–366.
26. Rachakonda PS, Hosen I, de Verdier PJ, et al. TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism. *Proc Natl Acad Sciences U S A*. 2013; 110(43): 17426–17431.
27. Ward DG, Baxter L, Gordon NS, et al. Multiplex PCR and next generation sequencing for the non-invasive detection of bladder cancer. *PloS one*. 2016; 11(2): e0149756.
28. Pivovarcikova K, Pitra T, Vanecek T, et al. Comparative study of TERT gene mutation analysis on voided liquid-based urine cytology and paraffin-embedded tumorous tissue. *Ann Diagn Pathol*. 2016; 24: 7–10.
29. Ward DG, Bryan RT. Liquid biopsies for bladder cancer. *Transl Androl Urol*. 2017; 6(2): 331–335.
30. Birkenkamp-Demtroder K, Christensen E, Nordentoft I, et al. Monitoring treatment response and metastatic relapse in advanced bladder cancer by liquid biopsy analysis. *Eur Urol*. 2017.
31. Pardini B, Cordero F, Naccarati A, et al. MicroRNA profiles in urine by next-generation sequencing can stratify bladder cancer subtypes. *Oncotarget*. 2018; 9(29): 20658–20669.
32. Babjuk M, Bohle A, Burger M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. *Eur Urol*. 2017; 71(3): 447–461.
33. Roupret M, Babjuk M, Comperat E, et al. European Association of Urology guidelines on upper urinary tract urothelial carcinoma: 2017 update. *Eur Urol*. 2018; 73(1): 111–122.
34. Kamat AM, Hegarty PK, Gee JR, et al. ICUD-EAU international consultation on bladder cancer 2012: Screening, diagnosis, and molecular markers. *Eur Urol*. 2013; 63(1): 4–15.
35. Tan WS, Sarpong R, Khetrpal P, et al. Does urinary cytology have a role in haematuria investigations? *BJU Int*. 2018 Jul 12. doi: 10.1111/bju.14459. [Epub ahead of print].
36. Meilleroux J, Daniel G, Aziza J, et al. One year of experience using the Paris System for Reporting Urinary Cytology. *Cancer Cytopathol*. 2018; 126(6): 430–436.
37. Wang Y, Auger M, Kanber Y, Caglar D, Brimo F. Implementing The Paris System for Reporting Urinary Cytology results in a decrease in the rate of the „atypical“ category and an increase in its prediction of subsequent high-grade urothelial carcinoma. *Cancer Cytopathol*. 2018; 126(3): 207–214.